Although PE is one of the most common male sexual disorders, it remains
widely under-diagnosed and under-treated. Most physicians do not screen for
PE and patients are extremely reluctant to talk about the condition with
their partners or health care professionals. PE can have a significant
impact on many aspects of a man's life. It can affect his and his partner's
sexual satisfaction and their ability to build and maintain relationships –
both sexual and non-sexual – and can impact a man's general sense of
self-confidence.
An observational study published in the May 2005 issue of The Journal of
Sexual Medicine found that patient-reported outcome measures (PROs), such as
control over ejaculation, satisfaction with sexual intercourse and distress
are important factors in assessing the benefit of treatments for PE in
clinical studies. The study found that men with PE and their partners
reported higher ratings for interpersonal difficulty, lack of control over
ejaculation and dissatisfaction with sexual intercourse.
Data presented on May 23 demonstrates that men taking dapoxetine
hydrochloride (see chemical structure above) for the treatment of premature
ejaculation (PE) experienced significant improvements in sexual function,
including ejaculatory control, satisfaction with sexual intercourse for men
and their partners, and increases in intravaginal ejaculatory latency time (IELT).
The U.S. Food and Drug Administration is currently reviewing a New Drug
Application for dapoxetine, which if approved, would be the first
prescription product indicated for the treatment of PE. These data were
presented at the 100th Annual Scientific Meeting of the American Urological
Association.
Read more
medical
news headlines, and
chemistry articles
Back to the sciencebase
homepage